11 January 2023 in Science Translational Medicine
Pancreatic and lung cancers frequently develop resistance to chemotherapy-induced cell apoptosis during the treatment, indicating that targeting nonapoptotic-related pathways, such as pyroptosis, can be an alternative cancer treatment strategy. Pyroptosis is a gasdermin-driven lytic programmed cell death triggered by inflammatory caspases when initiated by canonical or noncanonical pathways that has been recently seen as a potential therapeutic target in cancer treatment. However, overcoming chemoresistance in cancers by modulating pyroptosis has not been explored. Here, we demonstrate that β5-integrin represses chemotherapy-induced canonical pyroptosis to confer cancer chemoresistance through ASAH2-driven sphingolipid metabolic reprogramming. Clinically, high β5-integrin expression associates with poor patient prognosis and chemotherapeutic responses in cancers. In addition, chemoresistant cells in vitro fail to undergo chemotherapy-induced pyroptosis, which is controlled by β5-integrin. Mechanistically, proteomic and lipidomic analyses indicate that β5-integrin up-regulates sphingolipid metabolic enzyme ceramidase (ASAH2) expression through Src–signal transducer and activator of transcription 3 (STAT3) signaling, which then reduces the metabolite ceramide concentration and subsequent ROS production to prohibit chemotherapy-induced canonical pyroptosis. Using cancer cell lines, patient-derived tumor organoids, and orthotopic lung and pancreatic animal models, we show that administration of a Src or ceramidase inhibitor rescues the response of chemoresistant pancreatic and lung cancer cells to chemotherapy by reactivating pyroptosis in vitro and in vivo. Overall, our results suggest that pyroptosis-based therapy is a means to improve cancer treatment and warrants further investigation.
11 August 2026 in Cancer Research
Fasting-mimicking diets (FMD) have been reported to increase the antitumor efficacy in preclinical studies in various cancers. FMD can affect the tumor microenvironment (TME), and elucidating the mechanisms and cells mediating the effects of FMD may uncover combination treatment strategies. Here, we performed single-cell transcriptomic sequencing to characterize the TME changes induced by FMD intervention in a mouse model of spontaneous breast cancer. The sequencing data indicated that FMD suppressed tumor cell stemness, promoted apoptosis, and increased the infiltration of innate and adaptive immune cells, especially natural killer (NK) cells and effector CD8+ T cells. Importantly, FMD induced phenotypic reprogramming of cancer-associated fibroblasts (CAF), leading to a decrease in the immunosuppressive inflammatory CAF (iCAF) subset. Mechanistically, FMD decreased platelet-derived growth factor C (PDGFC) secretion in tumor cells by reducing glucose levels and inhibiting glycolysis to reprogram CAFs. PDGFC increased the activation of the JAK–STAT3 pathway, which induced iCAF differentiation. Combining FMD with PDGF receptor (PDGFR) inhibitors increased the efficacy of anti–PD-L1 immunotherapy in vivo. Overall, this study reveals a mechanism of metabolic–immune rewiring through which FMD suppresses tumor progression, providing preliminary evidence for the potential of combination FMD-based strategies in breast cancer treatment. Significance: Fasting-mimicking diet blocks breast cancer cell-induced generation of immunosuppressive fibroblasts, thereby facilitating tumor infiltration of immune cells and stimulating antitumor immunity to sensitize breast cancer to immunotherapy.
1 January 2025 in Journal of Breast Cancer
Zhang X, et al. J Breast Cancer. 2025 Feb;28:e7. https://doi.org/10.4048/jbc.2024.0223